ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00051493
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- You have a diagnosis of non-small cell lung cancer.
- You have received no prior chemotherapy.
- You have at least one measurable lesion.
- You have an adequate performance status.
- You are at least 18 years of age.
Exclusion Criteria
- You have previously received chemotherapy for your lung cancer.
- You have received radiation within the last 30 days.
- You have active infection or other serious condition.
- You have brain metastasis.
- You have recently lost a significant amount of weight.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method